[Ip-health] Congress, Administration Need to Act on Rx Prices, Lawmaker Says

Zack Struver zack.struver at keionline.org
Thu Apr 28 10:04:33 PDT 2016


Below are excerpts from a BNA article on Rep. Lloyd Doggett's recent
remarks at the Center for American Progress, including a section on Rep.
Doggett's remarks on the Xtandi petition at the NIH.

April 27, 2016
Congress, Administration Need to Act on Rx Prices, Lawmaker Says

>From Pharmaceutical Law & Industry Report

April 26 — Congress and the administration need to do more to address high
prescription drug prices, Rep. Lloyd Doggett (D-Texas) said April 26.

Doggett, a member of a task force of House Democrats examining the issue,
said Congress should pass legislation and the administration should use its
legal authority to address prescription drug prices. Doggett spoke during a
briefing of the Center for American Progress Action Fund. The fund
describes itself as a progressive think tank.

“In Congress, most of the health-care debate has been how many times we can
repeal Obamacare” and not about drug prices, Doggett said. “Our task force
is trying to change that and put drug prices back on the agenda.”

The task force to examine prescription drug prices was formed in January
(14 PLIR 72, 1/15/16). The task force is exploring the problem and
developing legislative solutions.


Doggett also said the administration could use its legal authority to
address the drug pricing issue.

One step the administration could take is to use its march-in rights under
the Bayh-Dole Act, he said. Under Bayh-Dole, the federal agency that funded
research leading to an invention can “march in” and issue patent licenses
on its own—thereby ignoring exclusivity rights—if “reasonable terms are not
being met’’ on drug pricing and if the agency has the intellectual property
on the drug's molecule.

In March, a group of Senate and House lawmakers led by Doggett and Rep.
Peter Welch (D-Vt.) sent a letter to the HHS and the National Institutes of
Health asking the NIH to hold a public hearing to consider using its
march-in rights to license generic versions of Astellas Pharma Inc.'s
prostate cancer drug Xtandi as part of an effort to reduce the drug's price
(14 PLIR 480, 4/1/16). Xtandi was developed at the University of
California, Los Angeles, through research grants from the U.S. Army and the
NIH. The medication has an average wholesale price in the U.S. of more than
$129,000 per year.

To contact the reporter on this story: Bronwyn Mixter in Washington at
bmixter at bna.com

To contact the editor responsible for this story: Brent Bierman at
bbierman at bna.com

For More Information

More information on the briefing is available at

Zack Struver, Communications and Research Associate
Knowledge Ecology International
zack.struver at keionline.org
Twitter: @zstruver <https://twitter.com/zstruver>
Office: +1 (202) 332-2670 Cell: +1 (914) 582-1428

More information about the Ip-health mailing list